Is there a generic Ozempic? Generic semaglutide and Sevmia
Reviewed 20 sourcesPublished by PepVault
Generic semaglutide is approved in Canada: Ozempic copies since April 2026 and Sevmia, a Wegovy copy, since June. The US has none yet. What each one is.

- Last reviewed
- Sources
- 20
- Questions
- 8
- Compounds
- 2
The short answer
Yes, in Canada. Health Canada approved the first generic semaglutide, a copy of Ozempic from Dr. Reddy's, on April 28, 2026, and Apotex's Sevmia, a copy of Wegovy, on June 29. Six generic products from four companies are approved there, and two are listed as marketed. The US has none: FDA's Orange Book lists no generic, and the main US patent runs to December 2031.
Evidence: Regulatory records: Health Canada's approvals, labels and registers and FDA's Orange Book, read on November 20, 2026, plus Novo Nordisk's SEC filings. No new clinical data.

Where is generic semaglutide approved?
Canada is the first G7 country to approve generic semaglutide1. Between April and September 2026, Health Canada authorized five generic copies of Ozempic, the type 2 diabetes pen, and one copy of Wegovy, the weight pen123456789. Every one is a weekly injection in a prefilled pen, sold on prescription. Health Canada's own list of generic submissions under review, current to September 30, 2026, still shows 11 more semaglutide files from companies including Teva, Taro, Zydus and Sandoz10.
| Country | Product | Company | Approved for | Date | Source |
|---|---|---|---|---|---|
| Canada | Semaglutide Injection (copy of Ozempic) | Dr. Reddy's | Type 2 diabetes | Apr 28, 2026; marketed May 6 | 14 |
| Canada | Apo-Semaglutide Injection (copy of Ozempic) | Apotex | Type 2 diabetes | May 1, 2026; marketed May 14 | 25 |
| Canada | Sevmia (copy of Wegovy) | Apotex | Chronic weight management, age 12 and up | Jun 29, 2026 | 36 |
| Canada | Aspen-Semaglutide (copy of Ozempic) | Aspen Pharmacare | Type 2 diabetes | Jul 17, 2026 | 7 |
| Canada | Semaglutide Injection (copy of Ozempic) | Aspen Pharmacare | Type 2 diabetes | Aug 25, 2026 | 8 |
| Canada | Sandoz Semaglutide (copy of Ozempic) | Sandoz | Type 2 diabetes | Sep 16, 2026 | 9 |
| United States | None approved | None | None | Orange Book file of Nov 13, 2026 | 1316 |
"Marketed" is Health Canada's own word in its Drug Product Database: the company has told the regulator the product is on sale. As of November 20, 2026, the Dr. Reddy's and Apotex diabetes pens carry it; Sevmia, the two Aspen pens and Sandoz's pen show "Approved", which means authorized but not yet reported as sold456789.

What is Sevmia?
Sevmia (sometimes misspelled "Svemia") is Apotex's generic copy of Wegovy, and the first generic semaglutide for weight that Health Canada approved3. Its Canadian label carries Wegovy's indications: chronic weight management with a reduced-calorie diet and more activity, in adults with a body mass index of 30 or more, or 27 or more with a weight-related condition such as high blood pressure or type 2 diabetes, and in teenagers 12 to 17 with obesity who weigh over 60 kg and have not lost enough with diet and activity alone. It also carries the reduction in the risk of a non-fatal heart attack in adults with heart disease and a BMI of 27 or more6.
One detail matters for anyone on the full dose. The label's ladder is Wegovy's: 0.25 mg a week, stepping up every 4 weeks through 0.5, 1 and 1.7 mg, so the 2.4 mg maintenance dose starts after week 166. But the only Sevmia pen in Health Canada's database, as of November 20, 2026, is a multi-use pen that delivers 1 mg doses (4 mg in 3 mL), and the label says it plainly: "SEVMIA can be prescribed only for 1 mg once weekly dosing. Alternative products are needed" for the other doses6. Wegovy itself has a marketed Canadian pen for every step, 0.25 mg to 2.4 mg20.
Is generic semaglutide the same as Ozempic?
It is the same molecule, in the same amounts, given the same way. Health Canada defines a generic as a copy of a brand-name drug with identical medicinal ingredients in the same amounts and a similar dosage form, absorbed at the same speed to a similar blood level11. The non-medicinal ingredients, such as buffers and preservatives, may differ, and the maker must show they change nothing about safety, efficacy or quality11.
The most interesting difference is how the molecule is made. Novo Nordisk grows Ozempic's and Wegovy's semaglutide in yeast: both Canadian labels say "produced by recombinant DNA technology in Saccharomyces cerevisiae"1220. Every generic label says "produced by solid-phase synthetic chemistry": the chain is built one building block at a time on a resin456. Health Canada calls the generics "complex synthetic products that are pharmaceutically equivalent to the brand name biologic drug" and says its review checks that the differences do not affect safety, efficacy or quality1.
| Pen | Ozempic (Novo Nordisk) | Generic Ozempic copies |
|---|---|---|
| How the semaglutide is made | Recombinant DNA, in yeast | Solid-phase chemical synthesis |
| Pen for 0.25 mg or 0.5 mg doses | Yes | Yes |
| Pen for 1 mg doses | Yes | Yes |
| Pen for 2 mg doses | Approved, not listed as marketed | None listed |
The doses are in milligrams on every pen, as on the brand. The pens are each company's own, with their own instructions and their own matched needles: Novo's label names NovoFine needles, Dr. Reddy's names Unifine Pentips and Apotex names Nano1245. Setting and giving a dose can feel different from the Novo pen you know.
How is a generic different from compounded semaglutide?
A generic is approved by a regulator before it is sold; a compounded drug is not. In the US, FDA says compounded drugs "are not FDA approved" and that the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed"15. A Canadian generic went through a full Health Canada review of its quality and its match to the brand, and it carries its own label and drug number111.
So "generic semaglutide" and "compounded semaglutide" are two different things, even when an ad uses one word for the other. What a compounded vial is, what FDA allowed during the shortage and when that ended has its own guide: compounded GLP-1s versus the brand.
Why did Canada get generic semaglutide first?
In Canada a new drug gets eight years of data protection: no copy can be approved by leaning on the brand's trial data until it ends, and no copy can even be filed in the first six. Health Canada's Register of Innovative Drugs gives Ozempic's dates: approved January 4, 2018, no filing before January 4, 2024, protection over on January 4, 202614. The first generic was approved less than four months later1.
Novo Nordisk names the effect itself. In its third-quarter 2026 report it writes that "in Canada, the loss of exclusivity for semaglutide has led to lower realised prices while volumes have remained broadly stable for Novo"17. In the US, the patents still stand, which is the next question.
When will generic Ozempic come to the US?
Not before the patents allow it, and the exact day is not public. FDA's Orange Book, the list of approved drugs and the patents that guard them, shows no approved generic semaglutide in its file of November 13, 202616. For both Ozempic and Wegovy it lists US patent 8,129,343, the patent on the semaglutide molecule itself, to December 5, 20311318. The table gives the latest dates across every Ozempic and Wegovy pen in the file16. Novo Nordisk's annual report gives the US compound patent expiry for Ozempic, Rybelsus and Wegovy as 203219.
| What the Orange Book lists | Ozempic | Wegovy |
|---|---|---|
| Patent on the molecule (8,129,343) | Dec 5, 2031 | Dec 5, 2031 |
| Latest listed patent | Feb 17, 2041 | Feb 17, 2041 |
| Latest listed exclusivity | Jan 28, 2028 (a new use) | Mar 19, 2029 (the 7.2 mg strength) |
Generic companies have already filed. Novo Nordisk reports that several makers filed abbreviated applications for generic Ozempic and Wegovy that challenge listed patents, that it sued, and that it has settled the Ozempic cases with seven companies: Alvogen, Rio, Sun, Dr. Reddy's, Mylan, Zydus and Apotex. "All terms of the agreements are confidential"19, so no US launch date for a generic is public.
Novo's older GLP-1, the daily injection liraglutide, shows how it went last time. Liraglutide (Victoza) lost its US compound patent in 2023; settled makers were licensed to launch from June 22, 2024, and the Orange Book's first approved generic liraglutide pen is Hikma's, dated December 23, 20241916.
What about other countries?
Novo Nordisk says the semaglutide compound patent has expired "in certain markets" outside the US and lists that among the pressures on its 2026 sales, without naming every country17. China is one place it has not: its Supreme People's Court upheld Novo's semaglutide compound patent in December 202519. We checked approvals only at Health Canada and FDA, so this guide lists no other country's generic until we have read that regulator's own record.
What does this mean if you take Ozempic or Wegovy now?
In Canada, a generic can replace the brand when your prescriber or pharmacist chooses it, at the same milligram dose. Outside Canada nothing changes yet: a Canadian approval covers Canada, and in the US the only approved semaglutide is Novo Nordisk's own: the Ozempic and Wegovy pens and the semaglutide tablets16.
- Same dose, new pen. The milligram dose carries over; the pen may work differently, so a first look with the pharmacist is worth it.
- Check the strength. Sevmia's only listed pen gives 1 mg doses, and no generic pen gives Ozempic's 2 mg dose yet64.
- Watch the date. A generic can change its status in Health Canada's database at any time; we re-read it each time this guide is reviewed.
Switching pens? PepVault's dose log keeps each weekly shot with its date and the dose you entered, so your record runs unbroken from the brand pen to the new one. Log it in PepVault
When to get help If you are unsure which dose a new pen gives, ask the pharmacist to show you before the first shot.
Sources
- Health Canada. Canada becomes the first G7 country to approve a generic version of semaglutide. News release, April 28, 2026. canada.ca
- Health Canada. Canada approves second generic semaglutide, the first G7 country to do so. News release, May 1, 2026. canada.ca
- Health Canada. Canada approves first generic semaglutide for weight loss. News release, June 29, 2026. canada.ca
- Health Canada Drug Product Database. Semaglutide Injection, Dr. Reddy's Laboratories, DIN 02567806, and its product monograph (authorized 2026-04-28). health-products.canada.ca
- Health Canada Drug Product Database. Apo-Semaglutide Injection, Apotex, DIN 02568012, and its product monograph (authorized 2026-05-01). health-products.canada.ca
- Health Canada Drug Product Database. Sevmia, Apotex, DIN 02569582, and its product monograph (authorized 2026-06-29). health-products.canada.ca
- Health Canada Drug Product Database. Aspen-Semaglutide, Aspen Pharmacare Canada, DIN 02569930 (authorized 2026-07-17). health-products.canada.ca
- Health Canada Drug Product Database. Semaglutide Injection, Aspen Pharmacare Canada, DIN 02570912 (authorized 2026-08-25). health-products.canada.ca
- Health Canada Drug Product Database. Sandoz Semaglutide, Sandoz Canada, DIN 02571501 (authorized 2026-09-16). health-products.canada.ca
- Health Canada. Generic submissions under review (list current as of 2026-09-30). canada.ca
- Health Canada. Access to generic drugs in Canada (fact sheet, modified 2024-05-07). canada.ca
- Health Canada Drug Product Database. Ozempic, Novo Nordisk Canada, DIN 02471469, and its product monograph. health-products.canada.ca
- FDA Orange Book. Ozempic (NDA 209637): patent and exclusivity information. accessdata.fda.gov
- Health Canada. Register of Innovative Drugs (semaglutide, submission 202059). canada.ca
- FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of 10/01/2026). fda.gov
- FDA. Orange Book data files (file dated November 13, 2026: products, patents and exclusivity). fda.gov
- Novo Nordisk. Financial report for the period 1 January 2026 to 30 September 2026, Form 6-K, filed November 4, 2026. sec.gov
- FDA Orange Book. Wegovy (NDA 215256): patent and exclusivity information. accessdata.fda.gov
- Novo Nordisk. Annual report on Form 20-F for 2025, filed February 4, 2026. sec.gov
- Health Canada Drug Product Database. Wegovy, Novo Nordisk Canada: DIN 02528525 (1 mg pen) and its product monograph; the marketed 0.25, 0.5, 1.7 and 2.4 mg pens are DINs 02528509, 02528517, 02528533 and 02528541. health-products.canada.ca
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.